Dopamine-induced changes in neural network patterns supporting aversive conditioning

Brain Research

Volumn 1313, Issue , 2010, Pages 143-161

  Diaconescu, Andreea Oliviana ^a,b   Menon, Mahesh ^c   Jensen, Jimmy ^d   Kapur, Shitij ^c,e   McIntosh, Anthony Randal ^a,b  

^a ROTMAN RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^d UNIVERSITY OF OSLO   (Norway)

^e KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Amphetamine; Aversive conditioning; Dopamine; fMRI; Functional connectivity; Haloperidol; Placebo controlled

Indexed keywords

AMPHETAMINE; DOPAMINE; HALOPERIDOL; PLACEBO;

ADULT; AMYGDALOID NUCLEUS; ANXIETY; ARTICLE; AVERSION; BRAIN FUNCTION; BRAIN REGION; CAUDATE NUCLEUS; CLINICAL ARTICLE; COLOR; CONDITIONED REFLEX; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC TRANSMISSION; ELECTROSTIMULATION; FEMALE; FRONTAL CORTEX; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; INSULA; LIMBIC SYSTEM; MALE; MENTAL TASK; MOTOR CORTEX; NERVE CELL NETWORK; PREFRONTAL CORTEX; PRIORITY JOURNAL; SKIN STIMULATION; STIMULUS RESPONSE; SUBICULUM; SUBSTANTIA NIGRA; TASK PERFORMANCE; UNITED STATES; VENTRAL TEGMENTUM; VISUAL STIMULATION;

ADULT; AMPHETAMINE; AVOIDANCE LEARNING; BRAIN; BRAIN MAPPING; CONDITIONING, CLASSICAL; DOPAMINE; DOPAMINE AGENTS; DOUBLE-BLIND METHOD; ELECTRIC STIMULATION; FEMALE; GALVANIC SKIN RESPONSE; HALOPERIDOL; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; NEURAL PATHWAYS; PHOTIC STIMULATION; RECEPTORS, DOPAMINE D2;

EID: 74349130197     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2009.11.064     Document Type: Article

References (77)

1. Abercrombie E.D., Keefe K.A., DiFrischia D.S., and Zigmond M.J. Differential effect of stress on in vivo dopamine release in striatum, nucleus accumbens, and medial frontal cortex. J. Neurochem. 52 (1989) 1655-1658
2. Alvarez R.P., Biggs A., Chen G., Pine D.S., and Grillon C. Contextual fear conditioning in humans: cortical-hippocampal and amygdala contributions. J. Neurosci. 28 (2008) 6211-6219
3. Amaral D.G., and Insausti R. Retrograde transport of D-[3H]-aspartate injected into the monkey amygdaloid complex. Exp. Brain Res. 88 (1992) 375-388
4. Angrist B., Corwin J., Bartlik B., and Cooper T. Early pharmacokinetics and clinical effects of oral d-amphetamine in normal subjects. Biol. Psychiatry 22 (1987) 1357-1368
5. Bechara A., Damasio H., Damasio A.R., and Lee G.P. Different contributions of the human amygdala and ventromedial prefrontal cortex to decision-making. J. Neurosci. 19 (1999) 5473-5481
6. Ben-Shakhar G. Standardization within individuals: a simple method to neutralize individual differences in skin conductance. Psychophysiology 22 (1985) 292-299
7. Berridge K.C., and Robinson T.E. What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience?. Brain Res. Brain Res. Rev. 28 (1998) 309-369
8. Buchel C., Morris J., Dolan R.J., and Friston K.J. Brain systems mediating aversive conditioning: an event-related fMRI study. Neuron 20 (1998) 947-957
9. Buchel C., Dolan R.J., Armony J.L., and Friston K.J. Amygdala-hippocampal involvement in human aversive trace conditioning revealed through event-related functional magnetic resonance imaging. J. Neurosci. 19 (1999) 10869-10876
10. Budhani S., Marsh A.A., Pine D.S., and Blair R.J. Neural correlates of response reversal: considering acquisition. Neuroimage 34 (2007) 1754-1765
11. Callaway E., Halliday R., Naylor H., Yano L., and Herzig K. Drugs and human information processing. Neuropsychopharmacology 10 (1994) 9-19
12. Carr D.B., O'Donnell P., Card J.P., and Sesack S.R. Dopamine terminals in the rat prefrontal cortex synapse on pyramidal cells that project to the nucleus accumbens. J. Neurosci. 19 (1999) 11049-11060
13. De la Casa L.G., Ruiz G., and Lubow R.E. Amphetamine-produced attenuation of latent inhibition is modulated by stimulus preexposure duration: implications for schizophrenia. Biol. Psychiatry 33 (1993) 707-711
14. Delaveau P., Salgado-Pineda P., Micallef-Roll J., and Blin O. Amygdala activation modulated by levodopa during emotional recognition processing in healthy volunteers: a double-blind, placebo-controlled study. J. Clin. Psychopharmacol. 27 (2007) 692-697
15. Delgado M.R., Li J., Schiller D., and Phelps E.A. The role of the striatum in aversive learning and aversive prediction errors. Philos. Trans R. Soc. Lond. B Biol. Sci. 363 (2008) 3787-3800
16. Delgado M.R., Nystrom L.E., Fissell C., Noll D.C., and Fiez J.A. Tracking the hemodynamic responses to reward and punishment in the striatum. J. Neurophysiol. 84 (2000) 3072-3077
17. Derogatis L.R., Lipman R.S., Rickels K., Uhlenhuth E.H., and Covi L. The Hopkins Symptom Checklist (HSCL): a self-report symptom inventory. Behav. Sci. 19 (1974) 1-15
18. Fallon J.H. Topographic organization of ascending dopaminergic projections. Ann. N. Y. Acad Sci. 537 (1988) 1-9
19. Fillmore M.T., Kelly T.H., and Martin C.A. Effects of d-amphetamine in human models of information processing and inhibitory control. Drug Alcohol. Depend 77 (2005) 151-159
20. Fletcher P.J., Tenn C.C., Rizos Z., Lovic V., and Kapur S. Sensitization to amphetamine, but not PCP, impairs attentional set shifting: reversal by a D1 receptor agonist injected into the medial prefrontal cortex. Psychopharmacology (Berl) 183 (2005) 190-200
21. Floresco S.B., and Magyar O. Mesocortical dopamine modulation of executive functions: beyond working memory. Psychopharmacology 188 (2006) 567-585
22. Friston K.J. Commentary and opinion: II. Statistical parametric mapping: ontology and current issues. J. Cereb. Blood Flow Metab. 15 (1995) 361-370
23. In: Friston K.J. (Ed). Statistical Parametric Mapping: The Analysis of Functional Brain Images (2007), Academic Press, London, England
24. Friston K.J., Frith C.D., Liddle P.F., and Frackowiak R.S.J. Functional connectivity: the principal-component analysis of large (PET) data sets. J. Cereb. Blood Flow Metabol. 13 (1993) 5-14
25. Garcia R., Vouimba R.M., Baudry M., and Thompson R.F. The amygdala modulates prefrontal cortex activity relative to conditioned fear. Nature 402 (1999) 294-296
26. Glover G.H., and Thomason M.E. Improved combination of spiral-in/out images for BOLD fMRI. Magn. Reson Med. 51 (2004) 863-868
27. Gray N.S., Pilowsky L.S., Gray J.A., and Kerwin R.W. Latent inhibition in drug naive schizophrenics: relationship to duration of illness and dopamine D2 binding using SPET. Schizophr. Res. 17 (1995) 95-107
28. Halliday R., Naylor H., Brandeis D., Callaway E., Yano L., and Herzig K. The effect of D-amphetamine, clonidine, and yohimbine on human information processing. Psychophysiology 31 (1994) 331-337
29. Hariri A.R., Mattay V.S., Tessitore A., Fera F., Smith W.G., and Weinberger D.R. Dextroamphetamine modulates the response of the human amygdala. Neuropsychopharmacology 27 (2002) 1036-1040
30. Honey G.D., Suckling J., Zelaya F., Long C., Routledge C., Jackson S., Ng V., Fletcher P.C., Williams S.C., Brown J., and Bullmore E.T. Dopaminergic drug effects on physiological connectivity in a human cortico-striato-thalamic system. Brain 126 (2003) 1767-1781
31. Horvitz J.C. Mesolimbocortical and nigrostriatal dopamine responses to salient non-reward events. Neuroscience 96 (2000) 651-656
32. Ikemoto S. Dopamine reward circuitry: two projection systems from the ventral midbrain to the nucleus accumbens-olfactory tubercle complex. Brain Res. Rev. 56 (2007) 27-78
33. Jensen J., McIntosh A.R., Crawley A.P., Mikulis D.J., Remington G., and Kapur S. Direct activation of the ventral striatum in anticipation of aversive stimuli. Neuron 40 (2003) 1251-1257
34. Jensen J., Smith A.J., Willeit M., Crawley A.P., Mikulis D.J., Vitcu I., and Kapur S. Separate brain regions code for salience vs. valence during reward prediction in humans. Hum. Brain Mapp. 28 (2007) 294-302
35. Jensen J., Willeit M., Zipursky R.B., Savina I., Smith A.J., Menon M., Crawley A.P., and Kapur S. The formation of abnormal associations in schizophrenia: neural and behavioral evidence. Neuropsychopharmacology 33 3 (2008) 473-479
36. Kalivas P.W., and Duffy P. Selective activation of dopamine transmission in the shell of the nucleus accumbens by stress. Brain Res. 675 (1995) 325-328
37. Kapur S., Mizrahi R., and Li M. From dopamine to salience to psychosis-linking biology, pharmacology and phenomenology of psychosis. Schizophr. Res. 79 (2005) 59-68
38. Kelly T.H., Foltin R.W., and Fischman M.W. The effects of repeated amphetamine exposure on multiple measures of human behavior. Pharmacol. Biochem. Behav. 38 (1991) 417-426
39. Knutson B., Bjork J.M., Fong G.W., Hommer D., Mattay V.S., and Weinberger D.R. Amphetamine modulates human incentive processing. Neuron 43 (2004) 261-269
40. LaBar K.S., Gatenby J.C., Gore J.C., LeDoux J.E., and Phelps E.A. Human amygdala activation during conditioned fear acquisition and extinction: a mixed-trial fMRI study. Neuron 20 (1998) 937-945
41. Luciana M., Depue R.A., Arbisi P., and Leon A. Facilitation of working memory in humans by a D2 dopamine receptor agonist. J. Cogn. Neurosci. 4 (1992) 58-68
42. Martin-Soelch C., Linthicum J., and Ernst M. Appetitive conditioning: neural bases and implications for psychopathology. Neurosci. Biobehav. Rev. 31 (2007) 426-440
43. Mattay V.S., Callicott J.H., Bertolino A., Heaton I., Frank J.A., Coppola R., Berman K.F., Goldberg T.E., and Weinberger D.R. Effects of dextroamphetamine on cognitive performance and cortical activation. Neuroimage 12 (2000) 268-275
44. McIntosh A.R. Mapping cognition to the brain through neural interactions. Memory 7 (1999) 523-548
45. McIntosh A.R., and Lobaugh N.J. Partial least squares analysis of neuroimaging data: applications and advances. Neuroimage 23 Suppl. 1 (2004) S250-S263
46. McIntosh A.R., Bookstein F.L., Haxby J.V., and Grady C.L. Spatial pattern analysis of functional brain images using partial least squares. Neuroimage 3 (1996) 143-157
47. Mehta M.A., McGowan S.W., Lawrence A.D., Aitken M.R., Montgomery A.J., and Grasby P.M. Systemic sulpiride modulates striatal blood flow: relationships to spatial working memory and planning. Neuroimage 20 (2003) 1982-1994
48. Menon M., Jensen J., Vitcu I., Graff-Guerrero A., Crawley A., Smith M.A., and Kapur S. Temporal difference modeling of the blood-oxygen level dependent response during aversive conditioning in humans: effects of dopaminergic modulation. Biol. Psychiatry 62 7 (2007) 765-772
49. Midha K.K., Chakraborty B.S., Ganes D.A., Hawes E.M., Hubbard J.W., Keegan D.L., Korchinski E.D., and McKay G. Intersubject variation in the pharmacokinetics of haloperidol and reduced haloperidol. J. Clin. Psychopharmacol. 9 (1989) 98-104
50. Montague P.R., Dayan P., and Sejnowski T.J. A framework for mesencephalic dopamine systems based on predictive Hebbian learning. J. Neurosci. 16 (1996) 1936-1947
51. Morris J.S., Ohman A., and Dolan R.J. A subcortical pathway to the right amygdala mediating "unseen" fear. Proc. Natl. Acad Sci. U. S. A. 96 (1999) 1680-1685
52. Nagano-Saito A., Leyton M., Monchi O., Goldberg Y.K., He Y., and Dagher A. Dopamine depletion impairs frontostriatal functional connectivity during a set-shifting task. J. Neurosci. 28 (2008) 3697-3706
53. Ousdal O.T., Jensen J., Server A., Hariri A.R., Nakstad P.H., and Andreassen O.A. The human amygdala is involved in general behavioral relevance detection: evidence from an event-related functional magnetic resonance imaging Go-NoGo task. Neuroscience 156 (2008) 450-455
54. Phelps E.A., Delgado M.R., Nearing K.I., and LeDoux J.E. Extinction learning in humans: role of the amygdala and vmPFC. Neuron 43 (2004) 897-905
55. Phelps E.A., O'Connor K.J., Gatenby J.C., Gore J.C., Grillon C., and Davis M. Activation of the left amygdala to a cognitive representation of fear. Nat. Neurosci. 4 (2001) 437-441
56. Robinson T.E., Becker J.B., Young E.A., Akil H., and Castaneda E. The effects of footshock stress on regional brain dopamine metabolism and pituitary beta-endorphin release in rats previously sensitized to amphetamine. Neuropharmacology 26 (1987) 679-691
57. Ruob C., Elsner J., Weiner I., and Feldon J. Amphetamine-induced disruption and haloperidol-induced potentiation of latent inhibition depend on the nature of the stimulus. Behav. Brain Res. 88 (1997) 35-41
58. Russig H., Murphy C.A., and Feldon J. Clozapine and haloperidol reinstate latent inhibition following its disruption during amphetamine withdrawal. Neuropsychopharmacology 26 (2002) 765-777
59. Sander D., Grafman J., and Zalla T. The human amygdala: an evolved system for relevance detection. Rev. Neurosci. 14 (2003) 303-316
60. Schmitz Y., Lee C.J., Schmauss C., Gonon F., and Sulzer D. Amphetamine distorts stimulation-dependent dopamine overflow: effects on D2 autoreceptors, transporters, and synaptic vesicle stores. J. Neurosci. 21 (2001) 5916-5924
61. Schoenbaum G., and Setlow B. Lesions of nucleus accumbens disrupt learning about aversive outcomes. J. Neurosci. 23 (2003) 9833-9841
62. Schwarz A.J., Gozzi A., Reese T., and Bifone A. Functional connectivity in the pharmacologically activated brain: resolving networks of correlated responses to d-amphetamine. Magn. Reson. Med. 57 (2007) 704-713
63. Schwarz A.J., Gozzi A., Reese T., Heidbreder C.A., and Bifone A. Pharmacological modulation of functional connectivity: the correlation structure underlying the phMRI response to d-amphetamine modified by selective dopamine D(3) receptor antagonist SB277011A. Magn. Reson. Imaging 25 (2007) 811-820
64. Servan-Schreiber D., Printz H., and Cohen J.D. A network model of catecholamine effects: gain, signal-to-noise ratio, and behavior. Science 249 (1990) 892-895
65. Seymour B., Daw N., Dayan P., Singer T., and Dolan R. Differential encoding of losses and gains in the human striatum. J. Neurosci. 27 (2007) 4826-4831
66. Seymour B., O'Doherty J.P., Dayan P., Koltzenburg M., Jones A.K., Dolan R.J., Friston K.J., and Frackowiak R.S. Temporal difference models describe higher-order learning in humans. Nature 429 (2004) 664-667
67. Takano A., Suhara T., Maeda J., Ando K., Okauchi T., Obayashi S., Nakayama T., and Kapur S. Relation between cortical dopamine D(2) receptor occupancy and suppression of conditioned avoidance response in non-human primate. Psychiatry Clin Neurosci. 58 (2004) 330-332
68. Tzschentke T.M. Pharmacology and behavioral pharmacology of the mesocortical dopamine system. Prog. Neurobiol. 63 (2001) 241-320
69. Ungless M.A., Magill P.J., and Bolam J.P. Uniform inhibition of dopamine neurons in the ventral tegmental area by aversive stimuli. Science 303 (2004) 2040-2042
70. Ventura R., Morrone C., and Puglisi-Allegra S. Prefrontal/accumbal catecholamine system determines motivational salience attribution to both reward- and aversion-related stimuli. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 5181-5186
71. Ventura R., Morrone C., and Puglisi-Allegra S. Prefrontal/accumbal catecholamine system determines motivational salience attribution to both reward- and aversion-related stimuli. Proc. Natl. Acad Sci. U. S. A. 104 (2007) 5181-5186
72. Weiner I., and Feldon J. The switching model of latent inhibition: an update of neural substrates. Behav. Brain Res. 88 (1997) 11-25
73. Weiner I., Shadach E., Barkai R., and Feldon J. Haloperidol- and clozapine-induced enhancement of latent inhibition with extended conditioning: implications for the mechanism of action of neuroleptic drugs. Neuropsychopharmacology 16 (1997) 42-50
74. Whalen P.J., Rauch S.L., Etcoff N.L., McInerney S.C., Lee M.B., and Jenike M.A. Masked presentations of emotional facial expressions modulate amygdala activity without explicit knowledge. J. Neurosci. 18 (1998) 411-418
75. Williams J.H., Wellman N.A., Geaney D.P., Cowen P.J., Feldon J., and Rawlins J.N. Antipsychotic drug effects in a model of schizophrenic attentional disorder: a randomized controlled trial of the effects of haloperidol on latent inhibition in healthy people. Biol. Psychiatry 40 (1996) 1135-1143
76. Williams J.H., Wellman N.A., Geaney D.P., Cowen P.J., Feldon J., and Rawlins J.N. Reduced latent inhibition in people with schizophrenia: an effect of psychosis or of its treatment. Br. J. Psychiatry 172 (1998) 243-249
77. Young A.M.J., Moran P.M., and Joseph M.H. The role of dopamine in conditioning and latent inhibition: What, when, where and how?. Neurosci. Biobehav. Rev. 29 (2005) 963-976